Last update 12 Sep 2024

Crinecerfont

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine, Crinecerfont Hydrochloride, NBI-74788
+ [3]
Target
Mechanism
CRHR1 antagonists(Corticotropin-releasing factor receptor 1 antagonists)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Rare Pediatric Disease (US), Orphan Drug (EU)

Structure

Molecular FormulaC27H29Cl2FN2OS
InChIKeyBMXALUHUEGRRCH-JIDHJSLPSA-N
CAS Registry321839-75-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adrenal Hyperplasia, CongenitalNDA/BLA
US
01 Jul 2024
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
US
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
BE
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
CA
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
FR
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
DE
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
GR
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
IT
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
PL
25 Jun 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 3
ES
25 Jun 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
8
oevllnrgef(pmviycjhgi) = vfrjjjnhzg zwoltvkjyn (kovtuvikit, uemcvonqvn - rubsypejld)
-
18 Jul 2024
Phase 3
103
djkqseyhfe(iyjvdcqipx) = rlsbtqoejc hphoilctzy (lqqdmcbkwp, -6.9)
Positive
02 Jun 2024
Placebo
djkqseyhfe(iyjvdcqipx) = lxpeblmtad hphoilctzy (lqqdmcbkwp, 2.5)
Phase 3
Adrenal Hyperplasia, Congenital
21-hydroxylase deficiency
182
ftgtannpuj(vuhqkyjyhh) = Fatigue were the most common adverse events in the two trial groups xierbbkryr (okzbfklfmv )
Positive
01 Jun 2024
Placebo
Phase 3
-
crinecerfont
ksozuqcpxx(dljxqhpexw) = a statistically significant decrease in serum androstenedione from baseline with crinecerfont at Week 4 over baseline, while both studies showed crinecerfont treatment led to statistically significant reductions in daily glucocorticoid from baseline while maintaining androgen control at Week 28 and Week 24, respectively ldieuubpkr (gpucdgvssp )
Positive
05 Dec 2023
Phase 2
18
(Cohort 1 (50 mg QHS))
xacuxscbmu(efyurjdolp) = hnykscrgex mfyocmfyxz (xsxqbtdkon, fhhndgfymd - nbjluvcmke)
-
03 May 2022
(Cohort 2 (100 mg QHS))
xacuxscbmu(efyurjdolp) = nilxzlyvip mfyocmfyxz (xsxqbtdkon, qttprjunuk - sbnlsltxqk)
Phase 2
18
wmihijjfla(mzaxkxxdux) = icidujnrds kbvomcimue (tgttdeuqxg )
Positive
17 Feb 2022
Phase 2
30
yqogyuvuac(ukisinhgci) = rgifukgbsc lpputdolbm (vdccskefmw )
Positive
12 Mar 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free